A transplant center designated as a Comprehensive Report Form center will submit data on the Pre-TED and Pre-TED Disease Classification Forms, followed by either the Post-TED Form or the Comprehensive Report Forms. The type of follow-up forms required for a specific recipient is determined by the CIBMTR’s form selection algorithm (see see Section 1 in the Center Reference Guide).

The Post-HCT Form (2100) must be completed at the following time points: 100 days, 6 months, annually for 6 years post-HCT, and biennially thereafter. This form should be completed as closely to these time points as possible. The following recipient data should be collected from an actual examination (or other recipient contact) by the transplant center physician or the local physician who is following the recipient post-HCT: vital status, hematopoietic reconstitution post-HCT, neutrophil recovery, platelet recovery, current hematologic findings, immune reconstitution, chimerism studies, engraftment syndrome, acute Graft-versus-Host Disease (GVHD), chronic GVHD, infections, organ function, new malignancy, functional status, and subsequent HCT.

Subsequent HCT:
If a recipient receives a subsequent HCT between time points (100 day, 6 months, annually), the CRF form sequence will start over again with another Pre-TED.

However, if the recipient receives an autologous HCT as a result of a poor graft or graft failure, the CRF form sequence will not start over again. Generally this type of infusion (autologous rescue) is used to treat the recipient’s poor graft response, rather than to treat the recipient’s disease, and is, therefore, not considered a subsequent HCT.

Contact your center’s CIBMTR CRC if the subsequent Pre-TED does not come due automatically.

Lost to Follow Up:
Occasionally, centers may lose contact with recipients for a variety of reasons, including the recipient’s moving, changing physicians, or death. If contact with a recipient appears lost, please consider calling the recipient at home or work, sending a letter, communicating with the treating or referring physician, or contacting the hospital billing department. If no documentation exists and several unsuccessful attempts have been made to contact the recipient, they are considered lost to follow-up and the form may be marked as such using the Lost to Follow-Up Tool in FormsNet3 for each reporting period in which no contact exists.

Links to Sections of the Form:

Q1-5: Vital Status
Q6-12: Granulopoiesis / Neutrophil Recovery
Q13-18: Megakaryopoiesis / Platelet Recovery
Q19-58: Growth Factor and Cytokine Therapy
Q49-63: Current Hematologic Findings
Q64-88: Immune Reconstitution
Q89-107: Chimerism Studies
Q108-130: Engraftment Syndrome
Q131-233: Acute Graft vs. Host Disease
Q234-406: Chronic Graft vs. Host Disease
Q407-427: Infection Prophylaxis
Q428-440: Infection
Q441-645: Organ Function
Q616-639: New Malignancy, Lymphoproliferative or Myeloproliferative Disease / Disorder
Q640-664: Functional Status
Q665-672: Subsequent HCT

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to reference the historical Manual Change History for this form, please click here or reference the retired manual section on the Retired Forms Manuals webpage.

Date Manual Section Add/Remove/Modify Description
12/22/2020 2100: Post-HCT Follow-Up Add Examples 7 and 8 were added to question 1, under the “Date of Contact and Subsequent Infusion” section.
12/22/2020 2100: Post-HCT Follow-Up Modify The definition of graft failure in questions 668-669 were updated to be consistent with the graft failure definitions on the 2400 and 2450: Additional hematopoietic stem cells are required because there wasn’t any ANC recovery following HCT (primary graft failure), the hematopoietic recovery indefinitely declined after the initial hematopoietic recovery (ANC was greater than or equal to 0.5 × 109/L for three consecutive days, and then declined to below 0.5 × 109/L for at least three consecutive days secondary graft failure), or hematopoietic recovery was deemed insufficient or too slow for survival following previous high-dose therapy and HCT. If autologous cells are infused for this reason, this is considered autologous rescue; in this case, reporting will continue under the prior HCT date and a new Pre-TED form is not required. This option also includes primary graft failure (no ANC recovery following HCT).
10/23/2020 2100: Post-HCT Follow-Up Modify Version 5 of the 2100: Post-HCT Follow-Up section of the Forms Instructions Manual released. Version 5 corresponds to revision 6 of the Form 2100.
Last modified: Dec 22, 2020

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.